Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986393 |
Synonyms | |
Therapy Description |
BMS-986393 (CC-95266) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting GPRC5D, which potentially results in antitumor activity (Blood (2022) 140 (Supplement 1): 883-885). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986393 | CC-95266|CC 95266|CC95266|BMS 986393|BMS986393 | BMS-986393 (CC-95266) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting GPRC5D, which potentially results in antitumor activity (Blood (2022) 140 (Supplement 1): 883-885). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06297226 | Phase II | BMS-986393 | Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL) | Recruiting | USA | CAN | 1 |